Trogenix strengthens scientific advisory board

Edinburgh-based biotech innovator Trogenix Ltd has appointed Professors Nada Jabado and Burkhard Becher to its scientific advisory board (SAB), further enhancing its capabilities in cancer research and therapy development.

Professor Jabado, a world-renowned expert in paediatric neuro-oncology, is professor of paediatrics at McGill University and a practising paediatric haematologist-oncologist at Montreal Children’s Hospital. 

Her groundbreaking work identified histone mutations as key drivers of paediatric gliomas, shifting the landscape of cancer research. 

Among her many honours, she is an Officer of the Order of Canada and a Fellow of the Royal Society of Canada.

Professor Becher, chair of experimental immunology at the University of Zurich, brings leading expertise in inflammation and immunotherapy. 

His research on cytokine signalling and immune cell networks has transformed understanding of neuroinflammation and cancer treatment. 

He is a recipient of the ERC Advanced Grant and a Clarivate Highly Cited Researcher.

The appointments strengthen Trogenix’s SAB, which includes global leaders in gene regulation, delivery, immunotherapy, oncology and regenerative medicine.

Steve Pollard, chief scientific officer at Trogenix, said: “We are honoured to welcome Nada Jabado and Burkhard Becher to our scientific advisory board. 

“Both are globally recognised leaders whose pioneering work in paediatric oncology and neuroimmunology, respectively, aligns perfectly with Trogenix’s mission to transform treatment paradigms for aggressive cancers. 

“Their insights will further elevate our already world-class SAB and each will provide invaluable guidance across our programmes and help guide future applications for our Odysseus platform.”

Looking to promote your product/service to SME businesses in your region? Find out how Bdaily can help →